Cuts in NIH funding have affected more than 74,000 people enrolled in 383 experiments
Cuts have led to patients losing access to treatments, and many have seen their clinical trials delayed or canceled
More than 74,000 people have been harmed by the National Institutes of Health (NIH) funding cuts, affecting 383 studies investigating treatments for critical illnesses.
This has led to disruptions in important clinical trials, from cancer research to infectious diseases. Researchers found that these cuts disproportionately affected efforts to combat diseases such as influenza, pneumonia, and COVID-19.
The cuts have led to patients losing access to treatments, and many have seen their clinical trials delayed or canceled. The lack of funding poses an obstacle to obtaining scientific evidence on the effectiveness of new treatments, reports the Associated Press (AP).
A recent report published in the journal JAMA Internal Medicine indicates that the loss of research harms patients who could have benefited from a potential new treatment.
Loss of trust in medical institutions
Funding disruptions could erode patients' trust in medical institutions.
Experts warn that uncertainty about the sustainability of trials could discourage future participants from getting involved in research. The Department of Health and Human Services administration defends the reorientation of priorities at the NIH. However, scientists and experts express concern about how these decisions, influenced by ideological agendas, harm public health and the mission of the NIH. Long-term effects of the cuts: Cuts to medical research have profoundly negative and diverse effects in the long term. First, they reduce the number of scientists who can conduct research, as support for doctoral studies and funding for new scientific projects decrease.This hinders the continuity of research on important medical topics and diseases, causing interruptions in active clinical trials that are essential for developing treatments and medical advances, especially in critical areas such as pediatric cancer, diabetes, HIV, and rare diseases.
Furthermore, these cuts affect medical innovation because they reduce grants that fund key basic research leading to pharmaceutical patents and the training of scientists for the biomedical industry.
They also negatively impact universities, especially public universities with fewer resources, dismantling scientific infrastructure and limiting the training of future professionals.
The reduction in funding affects epidemiological surveillance and the response to emerging diseases, jeopardizing essential prevention and vaccination programs, which can increase the incidence of preventable diseases.
Finally, it correlates with negative economic impacts, since cutting research and development spending by 25% could equate to a significant economic downturn.
Information on treatments that are canceled
When treatments are canceled In clinical trials, there are several alternatives for obtaining information about the treatments being evaluated:
In addition, clear and timely communication with patients is essential to provide information about cancellation, alternative processes, and the ongoing management of their health, which may include the use of technology to keep patients informed and facilitate monitoring of their treatment.